| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 2 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
147.37 |
29.47 |
176.84 |
4% |
5.89 |
153.26 |
30.65 |
183.91 |
16% |
23.58 |
176.84 |
35.37 |
212.21 |
корекц. решение НСР-5362/18.12.2014 |
НСР-3452/30.04.2014 |
|
|
Неактивен |
3519 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
62.59 |
12.52 |
75.11 |
4% |
2.5 |
65.09 |
13.02 |
78.11 |
16% |
10.01 |
75.1 |
15.02 |
90.12 |
НСР-16774/19.09.2018 (корекционно решение с предварително изпълнение) |
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г.; НСР-16687/30.08.2018; НСР-19170/04.07.2019 |
19.07.2019 |
02.08.2019 |
Активен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
62.59 |
12.52 |
75.11 |
4% |
2.5 |
65.09 |
13.02 |
78.11 |
16% |
10.01 |
75.1 |
15.02 |
90.12 |
НСР-16774/19.09.2018 (корекционно решение с предварително изпълнение) |
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г.; НСР-16687/30.08.2018; НСР-19170/04.07.2019 |
19.07.2019 |
02.08.2019 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
63.49 |
12.7 |
76.19 |
4% |
2.54 |
66.03 |
13.21 |
79.24 |
16% |
10.16 |
76.19 |
15.24 |
91.43 |
НСР-16774/19.09.2018 (корекционно решение с предварително изпълнение) |
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г.; НСР-16687/30.08.2018 |
14.09.2018 |
02.10.2018 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
64.31 |
12.86 |
77.17 |
4% |
2.57 |
66.88 |
13.38 |
80.26 |
16% |
10.29 |
77.17 |
15.43 |
92.6 |
|
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г. |
22.07.2016 |
02.08.2017 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml - 1 dose (0.2 ml) –, -, Pack: 1 pen contains 14 doses |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
64.31 |
12.86 |
77.17 |
4% |
2.57 |
66.88 |
13.38 |
80.26 |
16% |
10.29 |
77.17 |
15.43 |
92.6 |
|
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г. |
02.08.2016 |
02.08.2016 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
65.27 |
13.05 |
78.32 |
4% |
2.61 |
67.88 |
13.58 |
81.46 |
16% |
10.44 |
78.32 |
15.66 |
93.98 |
|
НСР-7301/29.10.2015 |
14.11.2015 |
14.11.2015 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
65.83 |
13.17 |
79 |
4% |
2.63 |
68.46 |
13.69 |
82.15 |
16% |
10.53 |
78.99 |
15.8 |
94.79 |
|
НСР-5293/ 18.12.2014. |
01.01.2015 |
01.01.2015 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
73.7 |
14.74 |
88.44 |
4% |
2.95 |
76.65 |
15.33 |
91.98 |
16% |
11.79 |
88.44 |
17.69 |
106.13 |
корекц. решение НСР-5362/18.12.2014 |
НСР-3452/30.04.2014 |
|
|
Неактивен |
3468 |
| Alemtuzumab |
EU/1/01/193/002 |
Mabcampath, Concentrate for solution for infusion, 30, mg, Pack: 3 |
Genzyme Europe B.V., Нидерландия |
Bayer Schering Pharma AG, Germany |
2342.34 |
468.47 |
2810.81 |
4% |
10 |
2352.34 |
470.47 |
2822.81 |
16% |
25 |
2377.34 |
475.47 |
2852.81 |
цената се заличава КЦРР-1548/01.11.2012 |
КЦ-353/19.12.2008 |
22.01.2009 |
22.01.2009 |
Заличен |
361 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Активен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.07.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
806.41 |
161.28 |
967.69 |
4% |
10 |
816.41 |
163.28 |
979.69 |
16% |
25 |
841.41 |
168.28 |
1009.69 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017 |
18.04.2017 |
02.05.2017 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
806.41 |
161.28 |
967.69 |
4% |
10 |
816.41 |
163.28 |
979.69 |
16% |
25 |
841.41 |
168.28 |
1009.69 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017 |
02.05.2017 |
02.05.2017 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
809.54 |
161.91 |
971.45 |
4% |
10 |
819.54 |
163.91 |
983.45 |
16% |
25 |
844.54 |
168.91 |
1013.45 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г. |
02.08.2016 |
02.08.2016 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100, mg/10 ml, Pack: 2 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
809.56 |
161.91 |
971.47 |
4% |
10 |
819.56 |
163.91 |
983.47 |
16% |
25 |
844.56 |
168.91 |
1013.47 |
|
НСР-6077/23.04.2015. |
08.05.2015 |
08.05.2015 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100, mg/10 ml, Pack: 2 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
827.94 |
165.59 |
993.53 |
4% |
10 |
837.94 |
167.59 |
1005.53 |
16% |
25 |
862.94 |
172.59 |
1035.53 |
|
НСР-4284/05.08.2014 |
20.08.2014 |
20.08.2014 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100, mg/10 ml, Pack: 2 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
836.61 |
167.32 |
1003.93 |
4% |
10 |
846.61 |
169.32 |
1015.93 |
16% |
25 |
871.61 |
174.32 |
1045.93 |
|
НСР-1920/27.11.2013 |
19.12.2013 |
19.12.2013 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100, mg/10 ml, Pack: 2 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
981.08 |
196.22 |
1177.3 |
4% |
10 |
991.08 |
198.22 |
1189.3 |
16% |
25 |
1016.08 |
203.22 |
1219.3 |
|
КЦ-529/13.02.2009 |
02.03.2009 |
02.03.2009 |
Неактивен |
3833 |